Abstract: The invention pertains to a method of optimizing the chemical precipitations process in water treatment plants and waste water treatment plants using an aluminum based coagulant, wherein the optimization, which comprises the degree of contamination of the Clear water phase after precipitation and sludge separation, cost of operation and sludge production, is obtained by in situ regulation, of precipitation pH, amount of coagulant that is used in the precipitation process and the basicity of the coagulant, based at least on online measurement of degree of contamination, pH, flow and temperature of incoming untreated water and/or in the clear water phase, characterized in that the basicity of the coagulant is regulated by adding in situ, to a stock solution of polymerized aluminum based coagulant (A), acid or a solution of an aluminum based coagulant (B) having a lower basicity than the polymerized aluminum based coagulant (A) in the stock solution.

Abstract: The present disclosure provides a radiotheranostic agent targeting LRRC15 expressed on cells derived from or associated with mesenchymal stem cells. The LRRC15 targeting agent would significantly improve diagnosis and treatment of a broad range of diseases and malignancies. In one embodiment, the LRRC15 targeting agent is a humanized monoclonal antibody (DUNP19) that has high binding affinity to LRRC15 and is internalized by cells expressing LRRC15.

Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Abstract: The invention pertains to a method of optimizing the chemical precipitations process in water treatment plants and waste water treatment plants using an aluminum based coagulant, wherein the optimization, which comprises the degree of contamination of the Clear water phase after precipitation and sludge separation, cost of operation and sludge production, is obtained by in situ regulation, of precipitation pH, amount of coagulant that is used in the precipitation process and the basicity of the coagulant, based at least on online measurement of degree of contamination, pH, flow and temperature of incoming untreated water and/or in the clear water phase, characterized in that the basicity of the coagulant is regulated by adding in situ, to a stock solution of polymerized aluminum based coagulant (A), acid or a solution of an aluminum based coagulant (B) having a lower basicity than the polymerized aluminum based coagulant (A) in the stock solution.

Abstract: The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.

Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Abstract: Presented herein are systems, compositions, and methods for immuno-PET/SPECT and/or immuno-fluorescence-guided imaging of tissue for diagnosing, localizing, radiation dose planning, and/or evaluating therapy response (e.g., anti-androgen receptor therapeutics, surgery and external irradiation) in cancer (e.g., androgen receptor (AR) positive breast cancer). In other embodiments, for example, the invention is directed to radio-immunotherapy (RIT) treatment of AR-positive breast cancer by administration (e.g., injection) of a free-PSA and/or free hK2 antibody labelled with a radioisotope after KLK2 and KLK3 induction by progesterone, testosterone, and/or irradiation.

Abstract: The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post-operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post-operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.

Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualization method, and diagnosing prostate cancer from the difference in visualization.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.

Abstract: Method for treatment of sludge, which includes precipitated aluminium and/or iron hydroxide, whereby the sludge first is added acid and thereafter is subjected to at least one membrane filtration process, whereby a permeate or a concentrate is obtained, including trivalent aluminium and/or iron ions in solution. The aluminium and/or iron ions in the permeate, or concentrate, are crystallised (salting out) in a precipitation.

Abstract: A method and construction for treatment of sludge from waterworks and wastewater treatment plants is disclosed. The method for treatment of sludge from waterwork or wastewater treatment plant, comprising precipitated inorganic chemical coagulants and precipitated organic substances, comprises adding an acid to the sludge in such a way that a first sludge mixture with low pH is received. The first sludge mixture includes the inorganic chemical coagulants in solution and the organic substances. The sludge mixture is pumped, via heat exchangers to a pressure tank. An obtained first concentrate is fed to at least one membrane filtration process in which a second concentrate and a first permeate are obtained.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.